Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Payables (2021 - 2025)

Roivant Sciences' Payables history spans 5 years, with the latest figure at $13.3 million for Q4 2025.

  • For Q4 2025, Payables fell 43.94% year-over-year to $13.3 million; the TTM value through Dec 2025 reached $13.3 million, down 43.94%, while the annual FY2025 figure was $23.7 million, 68.87% up from the prior year.
  • Payables reached $13.3 million in Q4 2025 per ROIV's latest filing, down from $15.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $194.6 million in Q2 2022 to a low of $11.5 million in Q2 2025.
  • Average Payables over 5 years is $38.9 million, with a median of $26.4 million recorded in 2024.
  • Peak YoY movement for Payables: surged 1196.18% in 2022, then plummeted 74.29% in 2023.
  • A 5-year view of Payables shows it stood at $24.4 million in 2021, then skyrocketed by 97.06% to $48.0 million in 2022, then decreased by 26.61% to $35.2 million in 2023, then tumbled by 32.69% to $23.7 million in 2024, then crashed by 43.94% to $13.3 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Payables are $13.3 million (Q4 2025), $15.1 million (Q3 2025), and $11.5 million (Q2 2025).